Associate, Insights Analyst, US Medical Affairs

Overview

We are seeking a detail-oriented, analytical, and curious Insights Analyst to monitor continuing medical education (CME) activities across both live in-person events and virtual platforms. In this entry-level role, you will be our “eyes and ears” on the ground and online—attending medical education sessions virtually and some in person, tracking qualitative and quantitative dynamics, capturing healthcare professional (HCP) feedback and quotes, and synthesizing key sentiment trends. Responsibility will include monitoring programs we support as well as ones we do not support but are relevant. The therapeutic areas covered include breast cancer and hematology. Your insights will directly inform our educational strategy, help evaluate CME programs and ensure our medical education offerings align with current healthcare provider needs.

Responsibilities

Educational Monitoring & Observation

• Virtual Event Monitoring: Attend and audit live online webinars, webcasts, and asynchronous online CME modules to ensure quality standards and track participant engagement.
• Live Event Coverage: Very limited in-person attendance for CME conferences, regional meetings, and symposiums to observe program execution, audience engagement, and session delivery.
• Audience Dynamics: Record key audience metrics, including attendance patterns, Q&A engagement levels, popular discussion topics, and overall event atmosphere.

HCP Sentiment & Data Capture

• Quote & Feedback Collection: Capture direct, non-attributed quotes, questions, and reactions from participating HCPs during session Q&A and panel discussions.
• Sentiment Analysis: Monitor and analyze HCP sentiment regarding clinical topics, treatment algorithms, therapeutic options, and educational gaps.
• Data Synthesis: Aggregate raw qualitative data (verbal feedback, chat logs, audience polling results) into structured datasets for further analysis.

Summary Reporting & Insights Delivery

• Post-Event Summaries: Draft clear, concise, and timely executive summary reports following each monitored program (typically within 48–72 hours).
• Trend and Theme Identification: Highlight recurring clinical questions, common misconceptions, areas of high interest, and emerging educational needs among HCPs.
• Cross-Program Analytics: Assist in compiling monthly, quarterly/trimester and annual aggregate sentiment reports to inform future CME content development and curriculum strategy and the Insights Reports.

Qualifications

Education & Experience

• Education: Bachelor’s degree required. Preferred majors include: Life Sciences (Biology, Biochemistry, Pharmacology, Public Health), Healthcare Administration / Health Communications, Communications or Market Research (with a strong interest in science/healthcare)
• Experience: 0–2 years of experience. Prior internships in medical communications, healthcare market research, event operations, or clinical settings are a strong plus.

Essential Skills &Competencies

• Strong Written & Verbal Communication: Ability to synthesize complex, technical medical information into clear, succinct executive summaries.
• Active Listening & Qualitative Capture: Exceptional listening skills with an eye for detail, capable of accurately capturing key quotes and underlying emotional/professional sentiments.
• Analytical Mindset: Comfortable organizing qualitative observations alongside quantitative metrics (polling, attendance numbers) into structured reports.
• Ability to function independently with the guidance of her/his manager, exercise good judgment and demonstrate strong decision-making skills.
• Tech-Savvy: Proficiency with virtual meeting platforms (Zoom, MS Teams, WebEx, Google) and reporting tools (Microsoft Office Suite, Google Workspace, survey platforms).
• Professionalism & Discretion: Ability to interact professionally with healthcare professionals and maintain strict confidentiality regarding proprietary content and HCP identities.

Travel & Work Environment

• CME Programs typically take place in the evenings (Eastern Standard Time). Willingness to watch these programs in the evenings on weekdays and approximately 10 programs occur on the weekends. These programs are 30 to 90 minutes in length. The candidate must be willing to watch these (primarily virtually) and deliver a summary report.
• Travel: Willingness and ability to travel within the United States in-person conference coverage Within 1 year, there would be up a maximum of 5 trips. Some of these congress meetings may be over weekends for larger congress meetings.

Base Salary Range of  $96,774 - $108,626. Menarini Stemline offers generous compensation and benefits packages, including Short Term Incentive Programs, Fidelity 401(k) (with company match of 6%), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

Menarini Stemline is committed to creating an inclusive environment for all employees.  All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

 

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

 

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

 

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of hematological and solid tumors. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

 

Additionally, Menarini received exclusive rights to commercialize Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

 

Menarini entered into a global license agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

 

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.